glp gip tirzepatide Molecular structure of and the dual activation mechanism of Personalized Compounded Tirzepatide Treatment

This activation suppresses appetite and enhances your body's response to insulin, making it more effective at processing sugar

Tirzepatide generally produces greater average weight loss than semaglutide and is often better tolerated, although both medications have similar gastrointestinal side-effect profiles

diabetic retinopathy (particularly with semaglutide) Medication interactions : Increased hypoglycemia risk when combined with insulin or sulfonylureas (dose reductions of these agents may be needed)

The information presented reflects clinical trial data and medical literature available as of publication date

Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss

Q4: How do I select the 0.5mg dose on the pen